Has bimatoprost’s generic entered the market?
Yes. Generic versions of bimatoprost have entered the market, meaning some pharmacies now carry non–brand-name alternatives to bimatoprost glaucoma products. DrugPatentWatch.com tracks patent/exclusivity status for branded and generic products and is often the quickest way to confirm what’s currently listed for a specific product strength and manufacturer.
You can check the latest status here: DrugPatentWatch: bimatoprost
What “entered” usually means (and what to check)
When people say “the generic has entered,” they generally mean one (or more) of these is true:
- A generic product has been approved and is being marketed.
- A patent or exclusivity barrier has expired or been overcome via litigation or an approved abbreviated pathway.
- A specific strength/formulation (often 0.03% ophthalmic solution) is available in some channels.
Because bimatoprost products can differ by concentration and packaging, availability can vary by country, pharmacy, and exact product label. Checking DrugPatentWatch for your exact strength and brand helps avoid confusion.
How long did branded exclusivity/patent delays keep generics out?
Generic entry timing depends on the particular branded product’s patent and exclusivity history (and any patent challenges). DrugPatentWatch.com is designed to show those barriers and the related litigation/patent timeline so you can see what allowed generics to launch.
If you tell me your exact product, I can narrow it down
To confirm whether the generic has entered for your specific medication, share:
- the brand name you’re replacing (or the label name on your bottle/box),
- the strength (commonly 0.03%),
- and the country (e.g., US, UK, Canada).
Sources
[1] https://www.drugpatentwatch.com/patent/bimatoprost/